Current Investments

Foresite Capital is building a portfolio to create enduring investor returns. Our current portfolio includes transformative, category-defining companies across the therapeutic, diagnostic, device and services sectors.

Acceleron Pharma
AcelRx Pharmaceuticals
Agile Therapeutics
Alder Biopharmaceuticals
Ambit Biosciences
BioDelivery Sciences
Epizyme
Ignyta, Inc.
Intarcia Therapeutics
Karyopharm Therapeutics
Keryx Biopharmaceuticals
Novavax, Inc
Orexigen Therapeutics
Puma Biotechnology
Scynexis
Sequenta
Sotera Wireless
Tarsa Therapeutics
Universal American Corporation
WaveTec Vision Systems
Xencor
Zafgen


Acceleron Pharma

Acceleron Pharma Inc. (Nasdaq:XLRN) aims to transform the lives of people suffering from cancer and orphan diseases by discovering and developing innovative therapies. Acceleron scientists have world-leading expertise in developing medicines that regulate the transforming growth factor beta (TGF-β) superfamily of proteins, which play fundamental roles in the growth and repair of cells and tissues such as red blood cells, bone, and blood vessels. Based on this expertise, Acceleron has built a robust pipeline of biologic therapies targeted to key mechanisms underlying blood diseases and cancer.

Back to Top

AcelRx Pharmaceuticals

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of pain and other conditions. It offers NanoTab, a tablet for oral transmucosal administration. The company also provides Sufentanil NanoTab PCA system, a sublingual patient-controlled analgesia system with a drug/device combination product candidate for the management of acute post-operative pain in the hospital settings; Sufentanil NanoTab BTP management systems for the treatment option for patients with cancer pain; and Sufentanil/Triazolam NanoTab, which provides analgesia and sedation for minor outpatient procedures. It serves patients, physicians, regulators, and payers.

Back to Top

Agile Therapeutics

Agile Therapeutics, Inc., a specialty pharmaceutical company, engages in the development of women's healthcare products. It offers a low estrogen dose seven day transdermal contraceptive patch system that delivers a combination of levonorgestrel and ethinyl estradiol. The company was founded in 1997 as Levotech, Inc. and changed its name to Agile Therapeutics, Inc. in April 2001. Agile Therapeutics, Inc. is based in Princeton, New Jersey.

Back to Top

Alder Biopharmaceuticals

Alder’s mission is to help alleviate human suffering by generating better and safer antibody therapeutics through novel technologies. Alder plays two roles:

As a biopharmaceutical company, Alder uses its proprietary technologies to uniquely identify, develop, produce and market its own antibody therapeutics. The work being done at Alder today will help those who suffer from cancer, autoimmune diseases, and inflammatory diseases.

As a licensing partner, Alder is revolutionizing the way the pharmaceutical industry discovers, develops and produces antibody therapeutics. Through various licensing agreements, Alder has used its proprietary technology to help major biopharmaceutical partners advance novel therapeutics to the clinic in less time and at lower cost. Alder's licensing strategy also includes identifying strategic partners to assist in the development and marketing of its preclinical and clinical pipeline programs.

Back to Top

Ambit Biosciences

Ambit Biosciences Corporation (Nasdaq: AMBI) is developing Quizartinib for patients with relapsed/ refractory acute myeloid leukemia (AML). Currently patients with relapsed AML have a very short life span and have no treatment alternatives. Ambit has demonstrated 75% response rates in AML patients with FLT-3+ mutations. It will be entering Phase 3 trials for registration in 1Q2014.

Back to Top

BioDelivery Sciences

BioDelivery Sciences (Nasdaq: BDSI) is a specialty pharmaceutical company with a focus in the areas of pain management and addiction medicine. The company is utilizing their novel and proprietary BioErodible MucoAdhesive (BEMA®) and other drug delivery technologies to develop and commercialize, either on their own or in partnership with third parties, new applications of proven therapies aimed at addressing important unmet medical needs.

BDSI's development strategy focuses on utilization of the Food and Drug Administration's (FDA's) 505(b)(2) approval process. This regulatory pathway allows them to potentially obtain more timely and efficient approval of new formulations of previously approved therapeutics

Back to Top

Epizyme

Epizyme is a clinical-stage biotechnology company focused on epigenetic treatments for cancer and has a proprietary platform for developing inhibitors of histone methyltransferases (HMTs), an important class of enzymes that control gene expression and is associated with tumorigenesis.

Back to Top

Ignyta, Inc

Ignyta, Inc. is a biotechnology company catalyzing personalized medicine in cancer. Ignyta is pursuing an integrated Rx/Dx strategy of combining highly targeted drug discovery and development with companion diagnostics for patient selection.

Back to Top

Intarcia Therapeutics

Intarcia Therapeutics, Inc., has developed a revolutionary device that could become a major treatment option for Type II diabetes. The device, ITCA 650, is a matchstick-sized osmotic pump that delivers GLP-1 (Glucagon-Like Peptide-1), an important therapy for diabetes, in a manner that avoids the need for regular, painful injections while producing efficacy and tolerability results that are potentially preferable to existing therapies.

Back to Top

Karyopharm

Karyopharm Therapeutics Inc. is a clinical-stage pharmaceutical company focused on discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and other major diseases. Karyopharm's scientific expertise is focused on the understanding of the regulation of intracellular transport between the nucleus and the cytoplasm. Karyopharm has discovered and developed novel, small molecule, Selective Inhibitors of Nuclear Export, or SINE, compounds that inhibit the nuclear export protein XPO1. In addition to cancer, Karyopharm believe's that their SINE compounds have the potential to provide therapeutic benefit in a number of additional indications, including autoimmune and inflammatory diseases, wound healing, HIV and influenza.

Back to Top

Keryx Biopharmaceuticals

Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) has developed Zerenex, an oral iron-based phosphate binder, which has recently successfully completed two Phase 3 trials (one in US, one in Japan) for the treatment of hyperphosphatemia in patients with end-stage renal disease (ESRD) requiring hemodialysis. Zerenex has equivalent phosphate removal to the market leader, Renagel, but also provides oral iron supplementation reducing Epogen and IV iron use, which are costly products with significant safety risks.

Back to Top

Novavax, Inc

Novavax, Inc. (Nasdaq: NVAX) is a clinical-stage biopharmaceutical company creating recombinant protein nanoparticle vaccines to address a broad range of infectious diseases. The company is developing a portfolio of vaccine candidates targeting seasonal and pandemic influenza (H5N1), a vaccine designed to protect children and the elderly against respiratory syncytial virus (RSV), rabies and other candidates.

Back to Top

Orexigen Therapeutics, Inc

Orexigen Therapeutics, Inc. (Nasdaq: OREX) is a biopharmaceutical company focused on the treatment of obesity. The Company's lead product candidate is NB-32. Based on successful results of the Light Study, an ongoing cardiovascular outcomes trial, Orexigen's strategy for NB-32 is to pursue approvals worldwide and pharmaceutical partnerships for global commercialization. The Company has submitted applications for marketing authorization in the United States and Europe, with potential approvals in 2014. If approved, North American partner Takeda Pharmaceuticals will commercialize NB-32 in the United States. The Company's other product candidate, Empatic, has completed Phase 2 clinical trials.

Back to Top

Puma Biotechnology

Puma Biotechnology, Inc. (NYSE: PBYI) is developing a powerful oral product for HER 2-positive breast cancer, an aggressive form of breast cancer. Puma’s lead product, neratanib is in Phase 3 registration clinical trials through a Special Protocol Assessment (SPA) with the FDA. Puma’s product may also play a role in treating other cancers, including non-small cell lung cancer.

Back to Top

Scynexis

Scynexis, Inc. operates as a drug discovery and development company in the United States and internationally. It engages in drug discovery, development, and manufacturing projects in various areas, such as antibacterials, antifungals, antiparasitics, antivirals, carbohydrates, central nervous system, controlled substances, kinases, natural products, neglected diseases, nuclear hormones, nucleosides, oncology, ophthalmology, pain, and prodrugs. The company offers SCY-635, a drug that is used for patients who are chronically infected with genotype 1 hepatitis C virus. It also provides contract research solutions, including medicinal chemistry, discovery biology, ADMET-PK, bioanalysis and analytical chemistry, process chemistry, and cGMP manufacturing. The company delivers drug pipeline solutions to pharmaceutical, health, and life science partners.

Back to Top

Sequenta

Sequenta, Inc. has developed a transformative diagnostic technology that could become the new standard in initial and follow up testing for patients suffering from various forms of leukemia and lymphoma. Using just a small vial of blood, Sequenta’s test, called ClonoSight, is able to determine the specific genetic sequence that uniquely identifies the leukemia or lymphoma cells that a patient has and uses that DNA fingerprint to track cancer cells circulating in the patient’s blood. By analyzing samples before, during and after treatment, this test can determine a patient’s initial response to treatment and monitor over time for “minimal residual disease” (MRD) and possible cancer relapse.

Back to Top

Sotera Wireless

Sotera Wireless, Inc. is a medical device company dedicated to the development, marketing and sale of a new generation of comprehensive vital signs monitoring. Sotera’s mission is to improve patient safety by empowering clinicians to detect early signs of deterioration in virtually any care setting and enable early intervention and rapid response, all without limiting the patient’s freedom of movement.

Back to Top

Tarsa Therapeutics

Tarsa Therapeutics, Inc. has developed an oral formulation of calcitonin, a recombinant peptide hormone that inhibits bone resorption, a key process underlying the development of post-menopausal osteoporosis.

Back to Top

Universal American Corporation

Universal American Corporation (NYSE: UAM) is an insurance, Finance and administrative services company that specializes in offering products to the senior and self-employed markets. UA Corp has targeted the senior market in particular because it is the fastest growing demographic segment in the country. UAC contracts with the federal government to offer Medicare Advantages with Prescription Drug Plans. Universal American is currently the 3rd largest Medicare Prescription Drug Plan organization and the Fifth largest Medicare Advantage Private-Fee-for-Service organization in the U.S.

Back to Top

WaveTec Vision Systems

WaveTec Vision Systems, Inc. has developed an intraoperative diagnostic instrument called ‘ORA with VerifEYE’, that significantly improves the ability of cataract surgeons to deliver the best possible surgical results. The device provides surgeons with real-time visualization of the eye’s anatomy and position throughout a cataract procedure and provides optimal selection of premium lens strength (especially useful for patients with previous Lasix surgery), placement of toric lens or guidance in concert with femtosecond lasers.

Back to Top

Xencor

Xencor, Inc. provides protein engineering technology platforms in the biotechnology industry.

Its products include antibody therapeutics, such as XmAb2513 for the treatment of relapsed Hodgkin’s lymphoma and anaplastic large cell lymphoma; XmAb5574, a humanized monoclonal antibody that targets the antigen CD19 for treatment of B cell malignancies; XmAb5592 for the treatment of myeloma; and XmAb5871 and XmAb7195, which are humanized monoclonal antibodies for the treatment of asthma and allergy. The company’s products also include XPro protein therapeutics, such as XPro1595, a dominant negative inhibitor for the treatment of multiple animal models of autoimmune and neuroinflammatory diseases.

Back to Top

Zafgen

Zafgen, Inc. is the world's first biopharmaceutical company dedicated to developing novel obesity therapeutics that directly target and shrink fat tissue to help the body regain and sustain a lean, healthy state. Adipose tissue (fat) is composed primarily of cells that store unused calories for later use. The balance between how the body stores excess calories and later accesses these depots when required plays a critical role in determining the overall size of the fat tissue, and therefore, an individual's weight. Zafgen's groundbreaking approach targets obesity at its biological foundation by safely restoring the balance of fat metabolism, driving the loss of fat and a return to a more healthy body weight. Zafgen's leadership and scientific advisors include the leading experts in obesity, metabolic disorders and medicinal chemistry.

Back to Top